Vir Biotechnology (VIR) Consolidated Net Income (2018 - 2026)
Vir Biotechnology recorded quarterly Consolidated Net Income of -$125.7 million in Q1 2026, down 192.84% quarter-over-quarter from -$42.9 million in Q4 2025, and down 3.91% year-over-year from -$130.8 million in Q1 2025.
Vir Biotechnology's Consolidated Net Income history runs 9 years deep, the most recent figure standing at -$125.7 million for Q1 2026.
- In Q1 2026, Consolidated Net Income fell 3.91% year-over-year to -$125.7 million; the TTM figure through Mar 2026 stood at -$442.7 million (up 23.36% YoY), while the FY2025 annual figure was -$438.0 million, up 16.09% from the prior year.
- Consolidated Net Income came in at -$125.7 million for Q1 2026 at Vir Biotechnology, down from -$42.9 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $518.6 million in Q1 2022 to a low of -$213.7 million in Q3 2024.
- A 5-year average of -$69.7 million and a median of -$116.0 million in 2023 frame the typical range for Consolidated Net Income.
- On a YoY basis, Consolidated Net Income climbed as much as 407.04% in 2022 and fell as far as 223.75% in 2022.
- Vir Biotechnology's Consolidated Net Income stood at -$101.6 million in 2022, then slipped by 14.14% to -$116.0 million in 2023, then climbed by 9.82% to -$104.6 million in 2024, then jumped by 58.96% to -$42.9 million in 2025, then slumped by 192.84% to -$125.7 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$125.7 million, -$42.9 million, and -$163.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | -125.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -125.70 Mn |
| Dec 31, 2025 | -42.92 Mn |
| Sep 30, 2025 | -163.14 Mn |
| Jun 30, 2025 | -110.96 Mn |
| Mar 31, 2025 | -120.97 Mn |
| Dec 31, 2024 | -104.59 Mn |
| Sep 30, 2024 | -213.72 Mn |
| Jun 30, 2024 | -138.38 Mn |
| Mar 31, 2024 | -65.28 Mn |
| Dec 31, 2023 | -115.97 Mn |
| Sep 30, 2023 | -163.41 Mn |
| Jun 30, 2023 | -194.78 Mn |
| Mar 31, 2023 | -140.96 Mn |
| Dec 31, 2022 | -101.60 Mn |
| Sep 30, 2022 | 175.31 Mn |
| Jun 30, 2022 | -76.49 Mn |
| Mar 31, 2022 | 518.62 Mn |
| Dec 31, 2021 | 525.25 Mn |
| Sep 30, 2021 | 110.43 Mn |
| Jun 30, 2021 | 61.81 Mn |
| Mar 31, 2021 | -168.91 Mn |
| Dec 31, 2020 | -116.74 Mn |
| Sep 30, 2020 | -84.61 Mn |
| Jun 30, 2020 | -31.17 Mn |
| Mar 31, 2020 | -77.24 Mn |
| Dec 31, 2019 | -63.77 Mn |
| Sep 30, 2019 | -48.31 Mn |
| Jun 30, 2019 | -33.93 Mn |
| Mar 31, 2019 | -28.67 Mn |
| Dec 31, 2018 | -26.39 Mn |
| Sep 30, 2018 | -33.46 Mn |